On January 5, 2022, Searchlight Pharma Inc., a leading Canadian-based specialty healthcare company focused on women's health, urogynecology, and urology, acquired ERFA Canada 2012 Inc.
ERFA is a Canadian-based distributor of niche pharmaceutical products across Canada that treat a range of underserved medical indications.
The combination of Searchlight and ERFA was transformational for Searchlight by adding a diverse portfolio of over 20 brands that significantly increase both scale and cash-flow, increasing Searchlight's expected double-digit growth. It strengthens Searchlight's women's health portfolio with the addition of Norlutate, a treatment for endometriosis, and it expands therapy with the addition of Thyroid, a treatment for hypothyroidism. The acquisition creates a compelling organization with attractive critical mass across products, business operations and infrastructure.
The acquisition was financed with low-cost, 8-year self-amortizing term debt provided by Fiera Private Debt, and with additional capital and support from existing shareholders.
Davies Ward Philips & Vineberg LLP was lead counsel for Searchlight Pharma Inc. on all aspects of the acquisition, including related financing, and is now the principal counsel to Searchlight for all commercial and strategic matters.